Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell therapy
Pharma
FDA approves first T-cell therapy for a solid tumor
Iovance priced Amtagvi, a one-time TIL therapy for melanoma, at a wholesale acquisition cost of $515,000 per patient.
Angus Liu
Feb 17, 2024 12:15pm
FDA sets date for high-profile CAR-T advisory committee meeting
Feb 2, 2024 1:31pm
FDA tweaks demand for boxed warning on Gilead's CAR-T label
Jan 24, 2024 10:29am
FDA wants classwide boxed warning on existing CAR-Ts
Jan 23, 2024 3:27am
CAR-T hype faces infrastructure reality check
Jan 15, 2024 3:00am
ASH: Study digs into FDA adverse event record of BCMA therapies
Dec 11, 2023 2:46am